Sling Therapeutics Will Present Linsitinib Trial Data
The study targets inflammation in thyroid eye disease, with Phase 3 testing now underway.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Should regulatory agencies expedite the approval process for new therapies for rare diseases?
Sling Therapeutics is set to release findings from its Phase 2b/3 LIDS trial on October 8, 2026, at the ASOPRS symposium. The company also confirmed that patient dosing for its subsequent Phase 3 ORBIT trial began in September 2026.
Why it matters
Thyroid eye disease is driven by the activation of IGF-1R, which leads to tissue expansion and inflammation. If effective, linsitinib offers a targeted approach to inhibiting this pathway to manage proptosis, or the bulging of the eye.
The LIDS trial randomized 90 participants to receive either 75 mg BID or 150 mg BID of linsitinib over a 24-week treatment period. Responders were then followed for a 48-week off-drug extension to monitor durability.
The players
Sling Therapeutics
An Ann Arbor-based developer of small-molecule therapies focused on thyroid eye disease and IGF-1R pathway inhibition.
U.S. FDA
The national regulatory agency that granted linsitinib Fast Track Designation to expedite the development of treatments for serious conditions.
The details
Linsitinib functions by inhibiting IGF-1R signaling—a protein receptor that regulates cell growth—to reduce inflammation and tissue expansion in the orbits. The LIDS study utilized a double-masked, placebo-controlled methodology to evaluate these effects. This process prevents both participants and researchers from knowing who received the active drug until the trial is unblinded.
Timeline
September 2026: First patients dosed in Phase 3 ORBIT trial.
October 8, 2026: Poster presentation of LIDS trial data at ASOPRS.
October 9, 2026: Oral presentation of LIDS trial data at ASOPRS.
The Tech Race
This development represents a critical data point for the growing field of targeted therapies for thyroid eye disease. By moving from a completed Phase 2b/3 study into the active Phase 3 ORBIT trial, the company is refining its approach to IGF-1R inhibition against evolving standards of care.
Patients and clinicians are currently awaiting the final presentation of the LIDS trial results to understand the drug's efficacy and safety profile. Until the Phase 3 ORBIT trial concludes, linsitinib remains an investigational treatment not yet available to the public.
The takeaway
The upcoming ASOPRS symposium will reveal the extent to which linsitinib can mitigate proptosis in clinical settings. Readers should monitor the ongoing Phase 3 ORBIT trial for the next major milestone in the drug's regulatory path.
Further reading
For more information on the current landscape of clinical development, visit Biotech.
More information
Find more details on the company's research pipeline at the Sling Therapeutics corporate website.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should regulatory agencies expedite the approval process for new therapies for rare diseases?
